Natera

NTRA

Market cap $24.1B

Overview Fund Activity

175.43 USD

+0.42

0.24%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

175.43

0.00

0%

1 day

0.24%

5 days

2.89%

1 month

8.86%

3 months

4.7%

6 months

17.54%

Year to date

9.23%

1 year

37.91%

5 years

187.87%

10 years

1,010.32%

About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Employees: 4,434

Healthcare Diagnostics & Research

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

123% more call options, than puts

Call options by funds: $105M | Put options by funds: $47.1M

104% more first-time investments, than exits

New positions opened: 110 | Existing positions closed: 54

36% more repeat investments, than reductions

Existing positions increased: 267 | Existing positions reduced: 197

21% more capital invested

Capital invested by funds: $18.2B [Q1] → $22B (+$3.87B) [Q2]

9% more funds holding

Funds holding: 591 [Q1] → 642 (+51) [Q2]

0.69% more ownership

Funds ownership: 95.1% [Q1] → 95.79% (+0.69%) [Q2]

21% less funds holding in top 10

Funds holding in top 10: 24 [Q1] → 19 (-5) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$170

3% downside

Avg. target

$208

18% upside

High target

$255

45% upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Stephens & Co. Mason Carrico	$183	Overweight Reiterated	15 Aug 2025
Piper Sandler David Westenberg	$220	Overweight Maintained	11 Aug 2025
RBC Capital Conor McNamara	$255	Outperform Maintained	8 Aug 2025
Barclays Luke Sergott	$210	Overweight Maintained	8 Aug 2025
Evercore ISI Group Daniel Markowitz	$170	Outperform Initiated	28 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about NTRA published over the past 30 days

Can Natera Stock Reach $500?

Let's start with something remarkable. Natera (NASDAQ: NTRA) just marked its 10th anniversary as a public company, and what a journey it has been.

Can Natera Stock Reach $500?

Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript

Natera, Inc. (NASDAQ:NTRA ) Baird Global Healthcare Conference 2025 September 9, 2025 8:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior Research Analyst All right, everyone.

Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript

Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability

For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside drivers, including positive cashflow, despite reported net losses. The company plays a key role in providing specialized testing solutions in the cancer-care and kidney-care space, among others.

Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability

Natera Provides Update on Patent Litigation with NeoGenomics

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc. The U.S. District Court for the Middle District of North Carolina issued a ruling invalidating certain claims in two patents that Natera asserted against NeoGenomics' v1.1 RaDaR test. Natera is evaluating its options, including an appeal and further enforcement with other patents. Impo.

Natera Provides Update on Patent Litigation with NeoGenomics

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). The study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current standard of care. It prospectively incorporates Signatera, Natera's personalized, tumor-informed molecular residual diseas.

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

Zacks Investment Research

Natera Shares Rise on the Launch of AI Platform for Precision Oncology

NTRA shares gain after unveiling its in-house AI platform, built on vast oncology datasets to transform precision cancer care.

Natera Shares Rise on the Launch of AI Platform for Precision Oncology

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain. The presentations underscore the strong clinical utility of Signatera in lung cancer. An analysis of early-stage, resectable non-small cell lung cancer (NSCLC) patients will be.

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers featuring its technology and reinforcing its long-standing commitment to robust clinical evidence and scientific research. These publications span high-impact journals – such as Nature, Nature Medicine, the American Journal of Transplantation and American Journal of Obstetrics and Gynecology – and high.

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These models and applications, which were developed in-house, are designed to drive innovation across therapeutic development, from early target discovery to real-time clinical decision support. The platform features a modular, multimodal architecture composed of three integrated layers: Data foundation.

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 utilizes the Signatera ctDNA test in patients with MIBC to detect molecular residual disease (MRD) in the bloodstream after surgery and predict who will benefit fro.

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

See News Rankings

Charts implemented using Lightweight Charts™